2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 245

Improvement in Fibromyalgia Symptoms and Skin Biopsy Results in Patients with Fibromyalgia and Small Fiber Neuropathy Treated with Intravenous Immune Globulin Infusion( IVIG)

Fibromyalgia and Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 197

Improving Clinical Decisions for Gout Management: Effect of Online Case-Based Education

Education Poster

9:00AM-11:00AM: Abstract Number: 466

Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR

Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

9:00AM-11:00AM: Abstract Number: 349

Improving the Performance of the Spanish Version of QOL-RA

Measures and Measurements of Healthcare Quality Poster – ARHP

9:00AM-11:00AM: Abstract Number: 54

In a Macaque Model of RA By Immunization with Citrullinated Peptides, the Valine in the 11 Position of the DRB1 Molecule Has Greater Impacts on T-Cell Response to Citrullinated Peptides Than the 70-74 Position in the Shared Epitope

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 394

In Patients with Suspected Idiopathic Inflammatory Myopathy, Does Pre-Biopsy Musculoskeletal MRI Result in Greater Yield of Diagnostic Biopsy Results? Summary of Data from a 10-Year Single Hospital Audit

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 321

In Rheumatoid Arthritis All Disease Activities Are Not Created Equal

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 48

In Vivo Demonstration of Tmtnf Reverse Signaling: Significance in the Therapeutic Response to Anti-TNF Agents during Murine Arthritis

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 158

Incidence and Prevalence of Antiphospholipid Syndrome in a Health Management Organization (HMO): A 15-Year Study

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 542

Incidence and Prevalence of Interstitial Lung Disease in the US Population and in Patients with RA By Anti-Citrullinated Protein Antibody Status

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 820

Incidence And Seasonal Variation Of Biopsy-Proven Giant Cell Arteritis – Revisited: A 20-Year Population-Based Study From Sweden

Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

9:00AM-11:00AM: Abstract Number: 512

Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 367

Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors

Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 273

Incidence of Systemic Lupus Erythematosus By Income: A Nationwide Study

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 722

Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].